文献速递心脑血管急症

中国大陆冠状动脉疾病患者他汀类药物治疗冗余临床试验的横断面研究

Effect of redundant clinical trials from mainland China evaluating statins in patients with coronary artery disease: cross sectional study.
PubMed 文献 · BMJ · 2021-02-02
一句话结论2008年后中国大陆开展的2045项冗余他汀试验中,未接受他汀的对照组患者额外发生3470例主要不良心脏事件,包括559例死亡。

该横断面研究检索截至2019年12月的文献数据库,纳入中国大陆2577项在冠状动脉疾病患者中比较他汀与安慰剂或不治疗的随机临床试验,共250810例患者。冗余试验定义为2008年(即指南强烈推荐他汀治疗后一年)之后启动或继续招募的随机临床试验。共识别2045项冗余试验,其对照组101486例患者未接受他汀治疗,随访24638人年,额外发生3470例主要不良心脏事件(95%CI 3230至3619),包括559例死亡(95%CI 506至612)、973例新发或复发心肌梗死(95%CI 897至1052)、161例卒中(95%CI 132至190)、83例需血运重建(95%CI 58至105)、398例心力衰竭(95%CI 352至448)、1197例复发或恶化性心绞痛(95%CI 1110至1282)及99例未指明主要不良心脏事件(95%CI 69至129)。作者认为冗余规模亟需改革以保护患者。

要点

  • 2008年后中国大陆2045项冗余他汀随机临床试验中,对照组101486例冠状动脉疾病患者未接受他汀治疗,随访24638人年。
  • 这些对照组患者额外发生3470例主要不良心脏事件(95%CI 3230至3619),其中死亡559例(95%CI 506至612)。
  • 额外事件还包括新发或复发心肌梗死973例(95%CI 897至1052)、卒中161例(95%CI 132至190)、需血运重建83例(95%CI 58至105)。
  • 冗余试验定义为2008年(指南强烈推荐他汀治疗后一年)之后启动或继续招募的随机临床试验。
  • 作者认为冗余规模亟需改革以保护患者。

适用人群与场景

  • 中国大陆2577项随机临床试验中任何类型冠状动脉疾病的250810例患者。
  • 冗余试验对照组为101486例未接受他汀治疗的冠状动脉疾病患者,随访24638人年。

诊断标准与关键阈值

  • 冗余临床试验定义为2008年(即指南强烈推荐他汀治疗后一年)之后启动或继续招募的随机临床试验。

研究设计与关键结果

  • 研究类型:横断面研究;检索截至2019年12月的文献数据库,纳入中国大陆2577项比较他汀与安慰剂或不治疗冠状动脉疾病患者的随机临床试验,共250810例患者。
  • 识别2045项冗余试验,发表于2008年至2019年,对照组101486例患者未接受他汀治疗,随访24638人年。
  • 对照组额外发生3470例主要不良心脏事件(95%CI 3230至3619),包括死亡559例(95%CI 506至612)、新发或复发心肌梗死973例(95%CI 897至1052)、卒中161例(95%CI 132至190)、需血运重建83例(95%CI 58至105)、心力衰竭398例(95%CI 352至448)、复发或恶化性心绞痛1197例(95%CI 1110至1282)、未指明主要不良心脏事件99例(95%CI 69至129)。

证据类型、等级与局限

  • 证据类型:横断面研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为冗余规模亟需改革以保护患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To identify redundant clinical trials evaluating statin treatment in patients with coronary artery disease from mainland China, and to estimate the number of extra major adverse cardiac events (MACEs) experienced by participants not treated with statins in those trials.

DESIGN: Cross sectional study.

SETTING: 2577 randomized clinical trials comparing statin treatment with placebo or no treatment in patients with coronary artery disease from mainland China, searched from bibliographic databases to December 2019.

PARTICIPANTS: 250 810 patients with any type of coronary artery disease who were enrolled in the 2577 randomized clinical trials.

MAIN OUTCOME MEASURES: Redundant clinical trials were defined as randomized clinical trials that initiated or continued recruiting after 2008 (ie, one year after statin treatment was strongly recommended by clinical practice guidelines). The primary outcome is the number of extra MACEs that were attributable to the deprivation of statins among patients in the control groups of redundant clinical trials-that is, the number of extra MACEs that could have been prevented if patients were given statins. Cumulative meta-analyses were also conducted to establish the time points when statins were shown to have a statistically significant effect on coronary artery disease.

RESULTS: 2045 redundant clinical trials were identified published between 2008 and 2019, comprising 101 486 patients in the control groups not treated with statins for 24 638 person years. 3470 (95% confidence interval 3230 to 3619) extra MACEs were reported, including 559 (95% confidence interval 506 to 612) deaths, 973 (95% confidence interval 897 to 1052) patients with new or recurrent myocardial infarction, 161 (132 to 190) patients with stroke, 83 (58 to 105) patients requiring revascularization, 398 (352 to 448) patients with heart failure, 1197 (1110 to 1282) patients with recurrent or deteriorated angina pectoris, and 99 (95% confidence interval 69 to 129) unspecified MACEs.

CONCLUSIONS: Of more than 2000 redundant clinical trials on statins in patients with coronary artery disease identified from mainland China, an extra 3000 MACEs, including nearly 600 deaths, were experienced by participants not treated with statins in these trials. The scale of redundancy necessitates urgent reform to protect patients.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Jia Y, Wen J, Qureshi R, et al. Effect of redundant clinical trials from mainland China evaluating statins in patients with coronary artery disease: cross sectional study. BMJ. 2021. PMID: 33531350. doi:10.1136/bmj.n48

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。